Get all your news in one place.
100's of premium titles.
One app.
Start reading
Fortune
Fortune
Prarthana Prakash

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Thomas Schinecker, chief executive officer of Roche (Credit: Pascal Mora—Bloomberg/Getty Images)

There’s no downplaying how lucrative the weight-loss drug industry is. 

Novo Nordisk, the Danish pharma giant, has seen its fortunes reach astronomical heights since its drugs, Ozempic and Wegovy, took off. Its shares have risen 432% in the last five years, and the company’s market cap far exceeds the size of Denmark’s economy—catapulted by the success of the weight-shedding injections. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.